KOSDAQBiotech & Pharma365660

Lemon Healthcare

₩2,220▼ 2.42%2026-11-18 close
Market Cap
₩29.9B
Turnover
₩500M
Volume
220K
Shares out.
13.5M
PER
—
PBR
1.9×
EPS
—
Dividend Yield
—

PER, PBR and dividend yield are calculated from the latest confirmed results (EPS, BPS, dividend per share) and the current share price · Prices as of the 2026-11-18 close

01

Report overview

Revenue growth, widening losses

Revenue rose 47.5% in the first nine months of 2026, yet the operating loss widened to KRW 2.74 billion, so top-line growth has not yet translated into profitability.

  1. 1

    Cumulative third-quarter 2026 revenue reached KRW 2.01 billion, up 47.5% year on year.

  2. 2

    Operating loss for the same period widened to KRW 2.74 billion versus the prior-year period.

  3. 3

    Nine-month results remain far from the company's 2026 targets of KRW 24.2 billion in revenue and KRW 6.6 billion in operating profit.

  4. 4

    Customer concentration is high, with a single client accounting for 81.8% of 2024 revenue from the Silson24 project.

  5. 5

    Equity turned positive in 2025 after redeemable preferred shares were converted to common stock, following full capital impairment at the end of 2024.

02

Business structure

Lemon Healthcare, founded in June 2017, operates a medical data relay platform built on its LDB technology, which converts non-standard hospital data into standard formats and delivers it to external demand institutions. The business has three segments.

LDB-H, the smart hospital service, is centered on hospital app construction and subscription fees, and subscription revenue was about KRW 1.5 billion of the KRW 5.0 billion segment revenue in 2025.

LDB-E, which relays medical data to insurers, pharmacies and public bodies and includes the Silson24 build-out, public SI projects and the Claim God service, generated KRW 9.9 billion in 2025 and accounted for more than half of total revenue.

LDB-D, covering processed data sales and advertising, is at an early stage, with its first data sales revenue of KRW 1.0 billion recorded in 2025. In competition, Lemon Talk overlaps with hospital search and appointment apps, while Claim God competes with a rapid private insurance claims service.

The company states that the LDB platform is used by about 80% of Korea's tertiary general hospitals, which it cites as its core advantage.

Revenue structure is shifting from one-off build-out SI revenue toward recurring maintenance and API-based subscription revenue, and the company projects recurring revenue at 40% in 2026 and 60% by 2028.

03

Recent trends

Cumulative third-quarter 2026 revenue was KRW 2.01 billion, up 47.5% year on year. Operating loss for the same period was KRW 2.74 billion, with losses continuing and widening compared with the prior-year period. Net loss was KRW 2.7 billion, moving in the same direction as the operating loss.

Looking at annual trends, revenue rose from KRW 6.05 billion in 2023 to KRW 14.87 billion in 2024 and KRW 15.95 billion in 2025.

Operating profit swung from a KRW 5.368 billion loss in 2023 to a KRW 127 million profit in 2024, before returning to a KRW 663 million operating loss in 2025, with higher personnel and commission costs cited as the main drivers.

In 2024, a single client accounted for 81.8% of revenue from the Silson24 project, and the top client share remained at 60.8% in 2025. Equity stood at minus KRW 31.2 billion at the end of 2024 after full capital impairment, largely because redeemable convertible preferred shares were recorded as liabilities.

After those shares were converted into common stock in 2025, total equity turned positive at KRW 2.2 billion, though the impairment ratio was still reported at 61.8%. Press reports indicated the stock opened more than 50% above the KRW 10,000 offering price on its first trading day, July 6, 2026.

The share price of KRW 2,235 as of 14:23 KST on November 18, 2026 is about 22% of the offering price, with market capitalization of KRW 30.1 billion and trading value of KRW 300 million.

04

Outlook

The company set targets of KRW 24.2 billion in 2026 revenue and KRW 6.6 billion in operating profit, and estimated 2027 revenue at KRW 29.6 billion. These targets assume expanded public SI build-out orders, stable Silson24 maintenance revenue, and higher advertising and data sales tied to its Health God service.

The offering valuation reflected an estimated 2027 net income of KRW 11.4 billion, applying an average price-to-earnings multiple of 25.5 times from comparable companies.

By contrast, the disclosed cumulative third-quarter 2026 revenue of KRW 2.01 billion and operating loss of KRW 2.74 billion mean that reaching the annual targets would depend heavily on second-half results. The company has said that revenue in this industry tends to concentrate in the fourth quarter.

Data distribution and trading services, along with data analytics services for insurers and pharmaceutical companies, are planned to launch in stages from 2027.

The timing of a return to operating profit, the pace of improvement in the capital impairment ratio, and changes in top-client concentration are the key indicators for the medium-term business model.

With the share price well below the offering price after listing, changes in trading volume and free float are also worth tracking.

05

Bull factors

National infrastructure track record via Silson24

Lemon Healthcare executed the Silson24 claims system build for the Insurance Development Institute, giving it experience running a nationwide medical data relay infrastructure.

According to the company, about 80% of Korea's tertiary general hospitals use its LDB platform, and its flagship Claim God service has reached 1.9 million cumulative subscribers and 10 million cumulative insurance claims.

This track record shows technology adoption by public agencies and hospitals and forms a base for follow-on public SI orders. These cumulative figures are company-reported.

Shift toward recurring subscription revenue

Revenue that was previously centered on one-off build-out projects is moving toward recurring structures such as maintenance, feature additions and API usage fees.

According to press reports citing the registration statement, Silson24 maintenance revenue was reflected at about KRW 4.8 billion in 2026 and KRW 4.6 billion in 2027. The company projects recurring revenue at 40% of the total in 2026 and 60% by 2028, and says its subscription renewal rate is around 95%. If this transition proceeds, the share of project-based revenue in the mix would decline.

Data business as an expansion option

The company has positioned its LDB-D segment, covering processed data sales and advertising, as a core rationale for its listing. Data sales generated KRW 1.0 billion in its first year of revenue in 2025, and the registration statement projected the segment growing to KRW 6.5 billion in 2027.

Advertising from the Health God service and a planned marketplace for medical AI training data are also cited as medium-term growth factors. The segment still contributes a small share of revenue and rests on estimates, so the pace at which it shows up in reported results is the key variable.

06

Bear factors

Persistent losses and a wide gap to targets

Cumulative third-quarter 2026 operating loss was KRW 2.74 billion, with losses widening versus the prior-year period. The company targeted KRW 24.2 billion in 2026 revenue and KRW 6.6 billion in operating profit, but nine-month revenue of KRW 2.01 billion leaves a wide gap to those targets.

The 2025 operating loss of KRW 663 million was attributed mainly to higher personnel and commission costs. Even allowing for the industry's fourth-quarter revenue concentration, a swing to profit depends heavily on second-half results.

A thin capital base

Equity stood at minus KRW 31.2 billion at the end of 2024 after full capital impairment, largely because redeemable convertible preferred shares were recorded as liabilities.

Conversion of those shares into common stock in 2025 turned total equity positive at KRW 2.2 billion, but the impairment ratio was still reported at 61.8%. With losses continuing on a thin capital base, financial flexibility remains a constraint. The resolution of the impairment will need to be confirmed in future financial statements.

Reliance on a few clients and public projects

A single client accounted for 81.8% of 2024 revenue from the Silson24 project, and the top client share was still 60.8% in 2025. Public and medical institution revenue made up 83.6% of the total in 2024 and 62.4% in 2025.

Results are shaped by government policy and budget execution timing, and one-off build-out SI revenue remains part of the mix. This lowers the predictability of quarterly results.

07

Risk factors

Macro

The timing of orders can shift with public budgets and policy schedules. The company has said it will strengthen its regulatory compliance framework for using medical data, and changes in that environment directly affect its scope of business.

Institutionalization of non-face-to-face care underpins demand for remote consultation and e-prescription services, but the pace of policy change can alter when that demand arrives.

Liquidity and supply-demand

As of 14:23 KST on November 18, 2026, trading value was KRW 300 million and market capitalization was KRW 30.1 billion. The share price of KRW 2,235 sits well below the KRW 10,000 offering price.

In the institutional book-building, the lock-up commitment ratio was only 6.91%, far below the 40% priority allocation benchmark. A thin trading value and a low lock-up ratio can add to share price volatility.

Regulatory and competitive

The medical data relay business is subject to regulation on personal and medical data. Lemon Talk competes with hospital search and appointment apps, and Claim God competes with a rapid insurance claims service.

The company has acknowledged that rivals could expand into smart hospital platforms, medical data relays and AI-based healthcare services. Estimates presented at the listing may not be fully achieved after the IPO, as is common for technology-listed companies.

08

Overall view

Lemon Healthcare operates a business built on public and medical data relay infrastructure, and its track record in nationwide projects such as Silson24 is cited as a key strength.

Cumulative third-quarter 2026 revenue was KRW 2.01 billion, up 47.5% year on year, but the operating loss widened to KRW 2.74 billion, so top-line growth has not yet translated into profit.

The most visible issue is the gap between the 2026 profit target and the nine-month results, following a 2025 operating loss after a 2024 swing to profit. On the financial side, equity turned positive in 2025, but the capital impairment ratio remains high and client concentration has not eased.

The shift to subscriptions and the expansion of the data business are presented as medium-term growth drivers, but they still make up a small share of revenue and their progress needs to show up in reported results.

The share price of KRW 2,235 is well below the KRW 10,000 offering price, and trading value of KRW 300 million is thin. This summary is a qualitative overview for information purposes only and does not include an investment rating or price target.

09

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 9 more articles and sources
  1. sedaily.com
  2. dataeconomy.co.kr
  3. newsway.co.kr
  4. etoday.co.kr
  5. v.daum.net
  6. m.news.nate.com
  7. kr.investing.com
  8. pharm.edaily.co.kr
  9. pharm.edaily.co.kr

Report written 2026-11-18 · Data as of 2026-11-17

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis